• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 502138 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417196973 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417196973 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Earnings Look Back: Seattle Genetics Is Up 3.6% Since Reporting Quarterly Results 1 Week Ago (SGEN)

Published on Sat, 05/18/2013 - 09:13
By Mallory Stone

A week ago on May 7th, 2013 Seattle Genetics (NASDAQ:SGEN) reported earnings and analysts, on average, expected a loss of $0.19 on sales of $53.6 million. Seattle Genetics actually reported a loss of $0.14 per share on sales of $57.3 million, beating EPS estimates by $0.05 and beating revenue estimates by $3.8 million. Shares of Seattle Genetics have climbed from $35.41 to $36.70, representing a gain of 3.6% since the company reported earnings 11 days ago.

In the past 52 weeks, shares of Seattle Genetics have traded between a low of $19.00 and a high of $39.00 and closed Thursday at $36.70, which is 93% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 2.2%.

Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company's technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer.

Seattle Genetics (NASDAQ:SGEN) defies analysts with a current price ($36.70) 14.4% above its average consensus price target of $31.40. The stock should discover initial support at its 50-day moving average (MA) of $35.58 and subsequent support at its 200-day MA of $28.72.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Cameco Crosses Below its 10-day MA (CCJ)...

Cameco (NYSE:CCJ) shares have crossed bearishly below their 10-day moving average of $1 ...

Harman International Industries Bearish ...

Today, shares of Harman International Industries (NYSE:HAR) have crossed bearishly belo ...

Bearish Moving Average Cross by KT (KT)...

Today, shares of KT (NYSE:KT) have crossed bearishly below their 10-day moving average ...

Bearish Moving Average Cross by Franco-N...

Today, shares of Franco-Nevada (NYSE:FNV) have fallen below their 10-day MA of $53.97 o ...

Bearish Moving Average Cross by Westlake...

Today, shares of Westlake Chemical (NYSE:WLK) have fallen below their 10-day MA of $68. ...

Bearish Moving Average Cross by Comerica...

Today, shares of Comerica (NYSE:CMA) have crossed bearishly below their 10-day moving a ...

Bearish Moving Average Cross by Wabtec (...

Today, shares of Wabtec (NYSE:WAB) have fallen below their 10-day MA of $89.83 on a vol ...

Teck Resources Crosses Below its 10-day ...

Teck Resources (NYSE:TCK) crossed under its 10-day moving average of $16.44 on a volume ...